BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29940170)

  • 1. MicroRNA: A new generation therapeutic target in diabetic nephropathy.
    Dewanjee S; Bhattacharjee N
    Biochem Pharmacol; 2018 Sep; 155():32-47. PubMed ID: 29940170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment.
    Yarahmadi A; Shahrokhi SZ; Mostafavi-Pour Z; Azarpira N
    Biochem Pharmacol; 2021 Jul; 189():114301. PubMed ID: 33203517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circular RNAs; powerful microRNA sponges to overcome diabetic nephropathy.
    Mafi A; Yadegar N; Salami M; Salami R; Vakili O; Aghadavod E
    Pathol Res Pract; 2021 Nov; 227():153618. PubMed ID: 34649056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients.
    Delić D; Eisele C; Schmid R; Baum P; Wiech F; Gerl M; Zimdahl H; Pullen SS; Urquhart R
    PLoS One; 2016; 11(3):e0150154. PubMed ID: 26930277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of expression of different microRNAs on insulin secretion and diabetic nephropathy progression.
    Mafi A; Aghadavod E; Mirhosseini N; Mobini M; Asemi Z
    J Cell Physiol; 2018 Jan; 234(1):42-50. PubMed ID: 30078212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic nephropathy: The regulatory interplay between epigenetics and microRNAs.
    Sankrityayan H; Kulkarni YA; Gaikwad AB
    Pharmacol Res; 2019 Mar; 141():574-585. PubMed ID: 30695734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of microRNAs in diabetic nephropathy.
    Wu H; Kong L; Zhou S; Cui W; Xu F; Luo M; Li X; Tan Y; Miao L
    J Diabetes Res; 2014; 2014():920134. PubMed ID: 25258717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
    Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
    BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.
    Kato M; Natarajan R
    Ann N Y Acad Sci; 2015 Sep; 1353(1):72-88. PubMed ID: 25877817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs and the glomerulus.
    Kato M; Park JT; Natarajan R
    Exp Cell Res; 2012 May; 318(9):993-1000. PubMed ID: 22421514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy.
    Rudnicki M; Beckers A; Neuwirt H; Vandesompele J
    Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv35-42. PubMed ID: 26209736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the role of MicroRNAs in diabetic nephropathy: Regulatory mechanisms and molecular insights.
    Abdelmaksoud NM; Al-Noshokaty TM; Abdelhamid R; Abdellatif N; Mansour A; Mohamed R; Mohamed AH; Khalil NAE; Abdelhamid SS; Mohsen A; Abdelaal H; Tawfik A; Elshaer SS
    Pathol Res Pract; 2024 Apr; 256():155237. PubMed ID: 38492358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies.
    Gholaminejad A; Abdul Tehrani H; Gholami Fesharaki M
    J Nephrol; 2018 Dec; 31(6):813-831. PubMed ID: 30019103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy.
    Kato M; Natarajan R
    Semin Nephrol; 2012 May; 32(3):253-60. PubMed ID: 22835456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy.
    Lv J; Wu Y; Mai Y; Bu S
    J Diabetes Res; 2020; 2020():3960857. PubMed ID: 32656264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of biological targets of therapeutic intervention for diabetic nephropathy with bioinformatics approach.
    Wu T; Li Q; Wu T; Liu HY
    Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):587-91. PubMed ID: 25003364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1.
    Peng R; Liu H; Peng H; Zhou J; Zha H; Chen X; Zhang L; Sun Y; Yin P; Wen L; Wu T; Zhang Z
    Gene; 2015 Oct; 570(1):57-63. PubMed ID: 26049093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy.
    Simpson K; Wonnacott A; Fraser DJ; Bowen T
    Curr Diab Rep; 2016 Mar; 16(3):35. PubMed ID: 26973290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-25 inhibits high glucose-induced apoptosis in renal tubular epithelial cells via PTEN/AKT pathway.
    Li H; Zhu X; Zhang J; Shi J
    Biomed Pharmacother; 2017 Dec; 96():471-479. PubMed ID: 29031207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA-NR_033515 promotes proliferation, fibrogenesis and epithelial-to-mesenchymal transition by targeting miR-743b-5p in diabetic nephropathy.
    Gao J; Wang W; Wang F; Guo C
    Biomed Pharmacother; 2018 Oct; 106():543-552. PubMed ID: 29990842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.